A. baumannii is an obligate aerobic coccus containing many potent virulence factors. It is an opportunistic pathogen that causes wound infections, pneumonia, meningitis, urinary tract infections, etc. in immunocompromised people. A. baumannii is also an important nosocomial pathogen, causing nosocomial and community infections worldwide. Moreover, it will produce multi-drug resistance to commonly used antibacterial agents, which has become the focus of attention.
The pathogenesis of A. baumannii infection is the result of multiple virulence factors such as capsules, lipopolysaccharide, and biofilm production. These virulence factors help organisms resist stressful environments and trigger severe infections. Combating A. baumannii infection is further complicated by challenging and diverse resistance mechanisms such as a broad spectrum of antibiotic hydrolases, efflux pump changes, impermeability, and antibiotic target mutations. Therefore, there is an urgent need to develop new therapies against A. baumannii infection.
Fig.1 Virulence determinants possessed of A. baumannii. (Ayoub Moubareck & Hammoudi Halat, 2020)
Pathogens that cause infections in hospitals and communities around the world place a huge burden on people's lives and property. In recent years, great progress has been made in polysaccharide vaccines against meningococcus, Haemophilus influenzae, and Staphylococcus aureus. The pathogenicity and virulence of Gram-negative bacteria are often associated with polysaccharides on the cell surface. Lipopolysaccharide (LPS) or lipooligosaccharide (LOS) is anchored to the cell surface by a highly conserved lipid A domain and is located in the outer leaflet of the outer membrane. As a potent virulence factor, LPS or LOS also are recognized by the host immune system as surface pathogen-associated antigens. Therefore, the development of bacterial LPS or LOS vaccines is of great interest.
As an advanced Glyco™ Vaccine Development company, CD BioGlyco provides our clients with high-quality LOS production on the surface of A. baumannii. We extract cell wall-bound polysaccharides from A. baumannii and treat them with RNase and DNase to degrade nucleic acids and proteins to obtain crude carbohydrates. Size exclusion chromatography (SEC) is used to separate crude carbohydrates and monitor the fractions. Each fraction is then purified by anion exchange chromatography (AEC). We have developed a variety of Conjugation Techniques to conjugate purified polysaccharides with target carrier proteins such as tetanus toxoid (TT) to obtain CPS-carrier protein conjugates.
Fig.2 Flowchart of polysaccharide vaccine production. (CD BioGlyco)
With well-equipped laboratories and a team of highly qualified scientists, CD BioGlyco provides high-quality polysaccharide antigen production services. We are looking forward to cooperating with enterprises, universities, and research institutes around the world. If you are interested in our services, please contact us for more details.
Reference:
